Rb has been found lost in 100% of NSCLC patients underwent histological transformation to small-cell lung cancer (SCLC) after gefitinib treatment [31], but no data are available on the phosphorylation status of Rb in patients with different mechanisms of resistance to EGFR-TKI. Here, RB1 is linked to non-small cell lung carcinoma.